Comments
The step-down wholly owned subsidiary of Strides Pharma Science has received approval from the US health regulator for potassium chloride extended-release tablets, used to treat hypokalemia. Hypokalemia occurs when the potassium levels of blood are too low.
“Strides Pharma Global Pte. Ltd, Singapore, has received approval for potassium chloride extended release tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (USFDA),” Strides Pharma Science said in a regulatory filing today.
Potassium chloride extended-release tablet is a generic version of Klor-Con extended-release tablet of Upsher-Smith and Strides is the first Indian generic company to receive this approval.
Quoting IQVIA MAT data, Strides Pharma Science said the US market for potassium chloride extended release tablets is approximately $60 million. The company said it has 78 cumulative ANDA filings with USFDA of which 52 ANDAs have been approved as of date and 26 are pending approval.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.